Health

Hemoglobin A1c (HbA1c) Diabetes Calculator

Calculator Free · Private

Data updated: 28 may 2026

Reviewed by: Martín Rodríguez (política editorial ) · Last reviewed: 28 may 2026

Was this calculator helpful?

Hemoglobin A1c (HbA1c, glycated hemoglobin) reflects your average blood glucose over the prior 8 to 12 weeks — essentially a 90-day rolling average that captures both fasting and postprandial excursions you would miss with a single finger-stick. According to the American Diabetes Association (ADA) Standards of Care 2026, an A1c below 5.7% is considered normal, 5.7% to 6.4% defines prediabetes (increased risk), and an A1c of 6.5% or higher on two separate occasions confirms a diabetes diagnosis. This calculator also converts your A1c percentage into estimated average glucose (eAG) in mg/dL using the Nathan regression equation: eAG = 28.7 × A1c − 46.7. Clinicians prefer A1c over fasting plasma glucose for screening because it requires no fasting, is less affected by acute illness or stress, and integrates intra-day glycemic variation that a single point measurement cannot capture. Important caveats: A1c is unreliable in patients with hemoglobinopathies (sickle cell trait, thalassemia), recent blood transfusion, hemolytic anemia, severe iron deficiency, advanced chronic kidney disease, or during pregnancy — in those scenarios continuous glucose monitoring (CGM) time-in-range, fructosamine, or glycated albumin should be used instead.

Last reviewed: May 27, 2026 Verified by Martín Rodríguez Source: ADA — Standards of Care in Diabetes 2026, NIDDK — A1C Test (National Institute of Diabetes and Digestive and Kidney Diseases), CDC — All About Your A1C, Nathan DM et al., Translating the A1C Assay Into Estimated Average Glucose Values (Diabetes Care, 2008), AACE — Comprehensive Type 2 Diabetes Management Algorithm 100% private

When to use this calculator

Prediabetes screening in adults age 35+ or with BMI ≥25 plus one risk factor (ADA 2026 USPSTF-aligned recommendation)
Confirming a diabetes diagnosis when fasting plasma glucose is borderline (≥126 mg/dL) — A1c ≥6.5% on a second test confirms
Tracking treatment response to metformin, GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors, or insulin titration
Evaluating GLP-1 effectiveness: expect a 1.0-2.0 percentage point A1c drop within 6 months on semaglutide 1.0-2.4 mg or tirzepatide 5-15 mg
Routine quarterly monitoring in type 2 diabetes patients not at goal (every 3 months); biannual when stable at target
Converting A1c to estimated average glucose (eAG) for patient education and CGM comparison
Assessing cardiovascular risk stratification in metabolic syndrome workups alongside lipid panel and blood pressure

Example Calculation

A1c = 7.0%
eAG = 28.7 × 7.0 − 46.7 = 154 mg/dL

Result: A1c 7.0% ≈ eAG 154 mg/dL (above ADA general T2D target of <7%)

How it works

3 min read

How HbA1c Reflects Your Average Glucose

Hemoglobin A1c forms when glucose in the bloodstream binds nonenzymatically to the beta chain of adult hemoglobin (HbA). Because red blood cells circulate for roughly 90 to 120 days, the percentage of glycated hemoglobin gives a weighted time-average of plasma glucose over the prior 8 to 12 weeks — with the most recent 30 days contributing approximately 50% of the value, the prior 30-60 days contributing about 25%, and the 60-120 day window contributing the remaining 25%. This is why a sudden improvement in glycemia (new GLP-1 prescription, dietary change) takes 6 to 12 weeks to fully register in your A1c.

eAG Conversion Table (Nathan Formula)

David Nathan and the A1c-Derived Average Glucose (ADAG) Study Group published the regression equation eAG (mg/dL) = 28.7 × A1c − 46.7 in Diabetes Care (2008), based on continuous glucose monitoring data from 507 subjects. The ADA endorses this conversion for patient counseling:

A1c (%)	eAG (mg/dL)	eAG (mmol/L)	Clinical interpretation
5.0	97	5.4	Normal
5.7	117	6.5	Prediabetes threshold
6.0	126	7.0	Prediabetes
6.5	140	7.8	Diabetes diagnostic threshold
7.0	154	8.6	General T2D target ceiling
8.0	183	10.2	Above goal — intensify therapy
9.0	212	11.8	Markedly uncontrolled
10.0	240	13.4	Very high — risk of complications
11.0	269	14.9	Severe hyperglycemia
12.0	298	16.5	Critical — urgent intervention

Accuracy Limitations and Hemoglobinopathies

A1c assumes a normal red blood cell lifespan and standard hemoglobin variants. Several conditions distort the result:

Sickle cell trait or disease (HbS), HbC, HbD, HbE: most modern HPLC and immunoassay methods are now hemoglobinopathy-tolerant, but boronate affinity is preferred. The NGSP maintains a list of A1c assays validated for variant hemoglobins.

Thalassemia, hemolytic anemia, recent blood transfusion: shortened red cell lifespan falsely lowers A1c.

Iron deficiency anemia, vitamin B12/folate deficiency: longer cell lifespan falsely elevates A1c by 0.3-0.5 percentage points.

G6PD deficiency: episodic hemolysis lowers A1c unpredictably.

Chronic kidney disease stage 4-5, dialysis: erythropoietin therapy and reduced red cell survival both lower A1c — use fructosamine or CGM instead.

Pregnancy: increased red cell turnover lowers A1c by 0.3-0.5 points — use the 2-hour 75g OGTT for gestational diabetes screening and CGM for type 1 management.

Target Ranges by Population (ADA 2026)

General nonpregnant adults with T2D: A1c <7% (eAG <154 mg/dL).

Older adults, multiple comorbidities, limited life expectancy, history of severe hypoglycemia: A1c <8% — overly tight control increases mortality (ACCORD trial).

Healthy older adults without major comorbidities: A1c <7.0-7.5%.

Pregnancy (preexisting T1D or T2D): A1c <6% if achievable without hypoglycemia, otherwise <6.5%.

Children and adolescents with T1D: A1c <7%, individualized.

Recently diagnosed, long life expectancy, no significant CVD: A1c <6.5% is reasonable when achievable without polypharmacy or hypoglycemia.

Time-in-Range (TIR): The Emerging Standard

Continuous glucose monitoring (CGM) is reshaping how endocrinologists evaluate glycemic control. Time-in-range (TIR), defined as the percentage of time spent between 70 and 180 mg/dL, correlates strongly with A1c — a TIR of 70% approximates A1c around 7%. CGM also reports time-below-range (TBR <70 mg/dL, target <4%) and time-above-range (TAR >180 mg/dL). The 2025 international consensus (Battelino et al.) supports TIR as a primary outcome metric in clinical trials, particularly because A1c alone misses hypoglycemic excursions and glycemic variability — both independent predictors of microvascular complications.

Impact of GLP-1 Receptor Agonists and SGLT2 Inhibitors

GLP-1 RAs (semaglutide, dulaglutide, liraglutide, tirzepatide) typically reduce A1c by 1.0-2.0 percentage points within 26 weeks and produce 5-15% weight loss — game-changing for type 2 diabetes management. Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist, achieves A1c reductions up to 2.4 points in the SURPASS trials. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower A1c by 0.5-1.0 points and confer independent cardiovascular and renal protection (EMPA-REG, DAPA-HF, CREDENCE). The ADA 2026 algorithm now recommends GLP-1 RAs or SGLT2 inhibitors as first-line add-ons to metformin in patients with established ASCVD, heart failure, or chronic kidney disease — regardless of A1c level.

Final Clinical Notes

A single A1c result is a screening or monitoring tool, not a standalone diagnosis. Confirm diabetes with a repeat A1c, fasting plasma glucose ≥126 mg/dL, 2-hour OGTT ≥200 mg/dL, or a random glucose ≥200 mg/dL with classic hyperglycemic symptoms. Always interpret A1c in the context of red blood cell biology, comorbidities, and pharmacotherapy. This calculator is an educational tool — clinical decisions belong with your endocrinologist or primary care clinician.

Frequently asked questions

What is a normal A1c level by age?

ADA 2026 sets a single nonpregnant adult threshold: normal <5.7%, prediabetes 5.7-6.4%, diabetes ≥6.5%. For older adults (65+) with multiple comorbidities or limited life expectancy, an individualized target of <8% is acceptable to avoid hypoglycemia. Healthy older adults without major comorbidities can aim for <7.0-7.5%. Children and adolescents with type 1 diabetes target <7%.

Can prediabetes (A1c 5.7-6.4%) be reversed?

Yes. The Diabetes Prevention Program (DPP) showed that 7% weight loss plus 150 minutes/week of moderate exercise reduces progression to type 2 diabetes by 58% over 3 years — more effective than metformin. Metformin reduces progression by 31% and is recommended for prediabetic patients under 60 with BMI ≥35 or a history of gestational diabetes. Many patients normalize their A1c within 6-12 months with sustained lifestyle change.

Why is there a discrepancy between my A1c and fasting glucose?

A1c reflects 90-day average glucose; fasting plasma glucose is a single time point. Discrepancies suggest: (1) postprandial hyperglycemia not captured by morning fasting (consider CGM or postprandial finger-sticks), (2) shortened or lengthened red blood cell lifespan distorting A1c (anemia, hemoglobinopathy, CKD), or (3) recent rapid glycemic change not yet reflected in A1c. If discrepancy persists, your endocrinologist may order fructosamine or glycated albumin.

Does anemia affect A1c results?

Yes, substantially. Iron deficiency anemia, vitamin B12/folate deficiency, and aplastic anemia lengthen red cell lifespan and falsely elevate A1c by approximately 0.3-0.5 percentage points. Conversely, hemolytic anemia, recent blood transfusion, thalassemia, and chronic kidney disease with erythropoietin therapy shorten red cell lifespan and falsely lower A1c. In these scenarios, fructosamine (2-3 week glucose average) or CGM-derived metrics are more reliable.

How much can GLP-1 medications lower my A1c?

Semaglutide 1.0-2.4 mg (Ozempic, Wegovy) typically reduces A1c by 1.5-1.8 percentage points within 26 weeks. Tirzepatide 5-15 mg (Mounjaro, Zepbound), a dual GIP/GLP-1 agonist, achieves up to 2.4-point reductions in the SURPASS trials. Dulaglutide and liraglutide deliver 1.0-1.5 point reductions. Most patients also lose 5-15% of body weight, which amplifies metabolic improvement. Effects plateau around 6-12 months.

Is time-in-range (TIR) better than A1c?

TIR (percent of time between 70-180 mg/dL on CGM) captures information A1c misses: hypoglycemia frequency, glycemic variability, and postprandial spikes — all independent predictors of microvascular complications. The 2025 international consensus (Battelino et al.) supports TIR ≥70% as a primary target for most patients with diabetes. A1c remains the validated endpoint for diagnosis and large-scale outcome trials, but for day-to-day management with CGM, TIR is now considered complementary or even superior.

How often should I test A1c in type 2 diabetes?

ADA 2026: every 3 months if not at glycemic goal or after any therapy change (new medication, dose titration). Every 6 months when stably at target with no recent therapy changes. Annually for adults with confirmed prediabetes. For type 1 diabetes, quarterly testing is standard. Pregnancy-complicated diabetes requires CGM with more frequent assessment.

Can stress, illness, or steroids raise my A1c?

Acute illness, infection, surgery, and corticosteroids (prednisone, dexamethasone) can elevate blood glucose for days to weeks. If sustained, this will raise A1c. Glucocorticoid-induced hyperglycemia is dose-dependent and reversible after tapering. Always disclose all medications — including over-the-counter steroids, antipsychotics (olanzapine, clozapine), and immunosuppressants — to your clinician before A1c interpretation.